Abuse of prescribed and other sedative drugs (e.g., benzodiazepines, barbiturates and ethanol) is among the top five health problems in the U.S. and is one of the most highly heritable addictive disorders. A host of biological (genetic) and environmental factors interact throughout the addictive process to influence drug use/abuse. Physiological dependence and associated withdrawal episodes are thought to constitute a motivational force that perpetuates sedative drug use/abuse and contributes to relapse. In humans, the identification of genes that influence drug dependence and withdrawal has been limited. Thus, the use of preclinical (animal) models that closely approximate the clinical situation is essential to elucidate the gene networks involved. We used these methods to identify two genes involved in sedative withdrawal in mice. The human homologs are now being studied in human populations by NIH intramural and other scientists. Quantitative trait loci (QTLs) are chromosome sites containing genes that influence a complex trait such as predisposition to drug withdrawal and consumption. Previously, we identified QTLs on chromosomes 1 and 4 with a large effect on sedative withdrawal in mice. During the current funding period, we fine-mapped these QTLs to 0.44 and 1.8 Mb intervals (syntenic with human 1q23.2 and 9p24-p22.3) and identified genes that code for MPDZ (the multi-PDZ domain protein) and GIRK3 (G-protein activated inwardly rectifying potassium channel subunit) as quantitative trait genes for drug withdrawal. Analyses of GIRK3 and MPDZ genetic models suggest that GIRK3 and MPDZ may also affect other addiction relevant phenotypes including sedative and cocaine self-administration. A key hypothesis of this proposal is that GIRK3 and MPDZ affect withdrawal from and self-administration (consumption) of multiple drugs of abuse. A second hypothesis is that the molecular network(s) associated with GIRK3 and MPDZ effects on behavior may interact at a mechanistic level.
The aims may be summarized: 1) To elucidate the roles of MPDZ and GIRK3 in drug withdrawal and self- administration using novel MPDZ and GIRK3 genetic models. 2) To elucidate brain regions involved in GIRK3 and MPDZ effects on behavior using chemical lesions as primary procedures. 3) To test the role of GABAB and 5-HT2C receptors in GIRK3 and/or MPDZ actions with central administration of selective agonist/antagonists to GIRK3 and MPDZ genetic models and wildtype littermates. 4) To elucidate the MPDZ and GIRK3 network signalosomes using weighted gene co-expression network analysis (WGCNA). Gene expression will be assessed using the Illumina array (e.g., beginning with the central nucleus of the amygdala) utilizing novel MPDZ and GIRK3 genetic models, using withdrawn and control mice. In addition to identifying differentially expressed genes, innovative de novo network construction will allow us to elucidate the underlying regulatory structure at a high level of integration. This can direct further mechanistic studies and elucidate the important network(s), within which many biomarkers and drugable targets may exist to direct translational studies.

Public Health Relevance

The proposed studies address genetic mechanisms involved in drug physiological dependence and associated withdrawal, and their broader role in addiction-relevant behaviors including self-administration. Elucidating the genetic bases of these mechanisms will provide a significant boost not only in understanding the underlying pathology but also in the development of new treatment strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA005228-23
Application #
8635321
Study Section
Neurotoxicology and Alcohol Study Section (NAL)
Program Officer
Pollock, Jonathan D
Project Start
1989-08-01
Project End
2016-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
23
Fiscal Year
2014
Total Cost
$283,500
Indirect Cost
$58,500
Name
Oregon Health and Science University
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Hitzemann, Robert; Bottomly, Daniel; Iancu, Ovidiu et al. (2014) The genetics of gene expression in complex mouse crosses as a tool to study the molecular underpinnings of behavior traits. Mamm Genome 25:12-22
Kruse, L C; Walter, N A R; Buck, K J (2014) Mpdz expression in the caudolateral substantia nigra pars reticulata is crucially involved in alcohol withdrawal. Genes Brain Behav 13:769-76
Tipps, Megan E; Raybuck, Jonathan D; Buck, Kari J et al. (2014) Delay and trace fear conditioning in C57BL/6 and DBA/2 mice: issues of measurement and performance. Learn Mem 21:380-93
Iancu, Ovidiu D; Oberbeck, Denesa; Darakjian, Priscila et al. (2013) Differential network analysis reveals genetic effects on catalepsy modules. PLoS One 8:e58951
Chen, Gang; Kozell, Laura B; Buck, Kari J (2011) Substantia nigra pars reticulata is crucially involved in barbiturate and ethanol withdrawal in mice. Behav Brain Res 218:152-7
Bottomly, Daniel; Walter, Nicole A R; Hunter, Jessica Ezzell et al. (2011) Evaluating gene expression in C57BL/6J and DBA/2J mouse striatum using RNA-Seq and microarrays. PLoS One 6:e17820
Chen, Gang; Cuzon Carlson, Verginia C; Wang, Jun et al. (2011) Striatal involvement in human alcoholism and alcohol consumption, and withdrawal in animal models. Alcohol Clin Exp Res 35:1739-48
Milner, Lauren C; Buck, Kari J (2010) Identifying quantitative trait loci (QTLs) and genes (QTGs) for alcohol-related phenotypes in mice. Int Rev Neurobiol 91:173-204
Chen, G; Buck, K J (2010) Rostroventral caudate putamen involvement in ethanol withdrawal is influenced by a chromosome 4 locus. Genes Brain Behav 9:768-76
McCool, Brian A; Christian, Daniel T; Diaz, Marvin R et al. (2010) Glutamate plasticity in the drunken amygdala: the making of an anxious synapse. Int Rev Neurobiol 91:205-33

Showing the most recent 10 out of 39 publications